Table 1 Clinical and sleep characteristics of multiple system atrophy (MSA) patients
From: Daytime sleepiness in Japanese patients with multiple system atrophy: prevalence and determinants
Variables | MSA patients |
|---|---|
Patients | 25 |
Male:Female | 10:15 |
Age at onset (years) | 62.3 ± 1.7 (46–78) |
Disease duration (months) | 45.9 ± 4.7 (12–96) |
UMSARS | 48.0 ± 4.0 (17–82) |
ESS | 6.2 ± 0.9 (0–15) |
Total sleep time (min) | 322 ± 18 (103–575) |
Sleep efficiency (%) | 61.9 ± 2.7 (35–95) |
Stage N1 (%) | 32.1 ± 2.26 (12.6–57.3) |
Stage N2 (%) | 46.3 ± 3.1 (11.4–69.8) |
Stage N3 (%) | 5.2 ± 1.4 (0–21.7) |
Stage REM (%) | 15.6 ± 2.5 (0–44.9) |
Arousal index (/h) | 43.0 ± 4.1 (0–79.9) |
AI (/h) | 19.7 ± 4.7 (0–80.8) |
AHI (/h) | 41.9 ± 6.4 (4.1–117.3) |
Mean SpO2 (%) | 93.1 ± 3.2 (82–97) |
PLM index (/h) | 44.2 ± 11.7 (0–166.0) |
PLM arousal index (/h) | 2.3 ± 0.9 (0–16.2) |
LED (mg/day) | 352 ± 50 (25–683) |